CPT Code 88305: The 2026 Billing and Compliance Guide for Surgical Pathology

The 88305 cpt code draws more audits than any other code in anatomic pathology, and this guide is built for the people who defend it on a claim: pathology labs, billing managers, and RCM teams handling high-volume specimen coding. It’s the Level IV surgical pathology code, and 88305 carries more denial exposure than any other code in the 88300-88309 family.

Two 2026 changes carry the most weight. CMS NCCI Policy Manual Chapter 10 mandates HCPCS G0416 for Medicare prostate needle biopsies, not the 88305 cpt code. The June 2026 NCCI MUE update, effective July 1, 2026, changes how pathology code pairs process at adjudication.

Those two facts drive most of the new denial volume, and the billing guidelines for cpt 88305 below address both.

This guide covers the AMA Level IV specimen list, the G0416 Medicare rule with named payer adoptions, the per-specimen jar rule, the complete modifier playbook (26, TC, 59, 91, XU), the 2026 Medicare fee schedule with named rates, MUE limits by diagnosis, and the NCCI bundling rules. Specific answers for the next claim, not a textbook overview.

CPT 88305 denials follow predictable patterns, and One O Seven RCM’s pathology billing team works these claims across every specimen type every day. Practices that want the full workflow managed can lean on our revenue cycle management services.

This guide reflects CMS NCCI Policy Manual Chapter 10 (effective January 1, 2026), the College of American Pathologists CMS Impact Table (July 2025 update), Palmetto GBA surgical pathology documentation requirements, and the CMS MUE quarterly posting as of June 2026.

What Is CPT Code 88305: The Official AMA Descriptor and Level IV Definition

The Verbatim AMA Descriptor for CPT 88305

The 88305 cpt code description comes from the AMA CPT codebook, and the 88305 cpt code carries the Level IV label as part of its official descriptor. The descriptor reads as a distinct entry:

“Level IV: Surgical pathology, gross and microscopic examination.”

That Level IV header descriptor appears in the CPT codebook and the NIH VSAC code system, with the full specimen-level entry confirmed by the AAPC code reference. [VERIFY the exact codebook descriptor wording and Level IV label against the current AMA CPT codebook before publishing.]

CPT 88305 is one of six surgical pathology levels in the 88300-88309 range. The level isn’t set by diagnosis severity or technique complexity. The cpt code 88305 definition turns on specimen type, as listed in the AMA CPT Level IV specimen catalog.

The AMA maintains this code under the Pathology and Laboratory Procedures section (CPT codes 80047-89398). Common places of service include independent laboratories (POS 81), physician office labs (POS 11), and on-campus hospital outpatient departments (POS 22). It sits in the surgical pathology level iv tier of that section.

Per the AAPC Codify CPT 88305 reference, the physician, a pathologist in most cases, performs a Level IV examination of a surgical pathology specimen. The AMA CPT descriptor for 88305 is “Level IV: Surgical pathology, gross and microscopic examination,” per the American Medical Association CPT codebook referenced by AAPC Codify and the NIH VSAC code system.

This code applies to moderate-complexity specimens where a pathologist performs both gross (visual) and microscopic (cellular) examination.

Billing Translation: What the Descriptor Requires Your Documentation to Prove

The AMA descriptor creates four documentation requirements for every 88305 cpt code claim. All four have to be satisfied for the claim to pass coverage screening.

Requirement 1: Gross examination. The pathologist inspects the specimen by eye and documents its size, shape, color, and visible abnormalities. The gross description has to appear in the final pathology report. A claim with no documented gross examination can’t be defended as 88305.

Requirement 2: Microscopic examination. The pathologist examines tissue sections under a microscope and documents the cellular findings. Both gross and microscopic components are required. Billing 88305 with no documented microscopic examination is overcoding when only gross examination was performed.

Requirement 3: Level IV specimen type. The specimen type has to be on the AMA’s Level IV specimen list. Billing 88305 for a specimen assigned to Level III (88304) or Level V (88307) is a level selection error regardless of what the pathologist found.

Requirement 4: Signed pathology report. The final diagnosis, gross description, microscopic findings, and pathologist’s signature have to appear in the completed report.

Per CGS MAC probe review findings for 88305, claims have been denied even with a signed pathology report on file because the treating clinician’s order or intent to order was missing. The documentation section below covers this in full. [VERIFY the CGS MAC probe review finding and citation before publishing.]

The Surgical Pathology Code Ladder: Where 88305 Sits in the 88300-88309 Family

The Complete 88300-88309 Code Ladder for 2026

Surgical pathology level selection is the most consequential coding decision in the cpt 88305 cluster, and the most common source of audit exposure. The level is driven by specimen type, not by diagnostic findings.

2026 Surgical Pathology Code Ladder (88300-88309)

A lipoma is 88304 whether it’s benign or malignant. A colon polyp is 88305 whether it’s an adenoma or an adenocarcinoma. The diagnosis discovered on microscopy doesn’t change the level. The specimen type submitted determines it, which is the core surgical pathology level iv rule, also written surg path level iv in lab shorthand.

88304 vs 88305 vs 88307: The Level Selection Decision Guide

Code 88304 (Level III) is correct when the specimen is a lower-complexity tissue type in the AMA Level III catalog. Examples from the CPT codebook: lipoma, simple cyst, foreskin (newborn), and fallopian tube for sterilization procedures. That settles the difference between cpt code 88304 and 88305 at the specimen level.

Code 88307 (Level V) is correct when the specimen involves a complex resection requiring detailed surgical margin evaluation. The clearest example, per the APS Medical Billing whitepaper: a breast margin specimen where the pathologist documents margin evaluation in the Final Diagnosis uses 88307.

A breast margin with no documented margin evaluation uses 88305. That settles the difference between cpt code 88305 and 88307.

Some specimens change levels based on the final diagnosis, the exception to the specimen-type rule. CMS and coding guidance use the uterus example: a uterus removed for fibroids is 88307, and a uterus removed for cancer is 88309. The 88305 cpt code doesn’t apply to either uterine resection.

Here’s the RCM-safe rule from the 2026 official data: pick the surgical pathology level based on the specimen submitted and the required work, consistent with CPT and payer policy, not on the diagnosis discovered on microscopy alone. Make the documentation support the level billed. That’s level 4 surgical pathology selection done right.

Level selection errors carry audit consequences. CGS MAC probe review findings for 88305 identified cases where documentation didn’t support 88305, meaning the specimen type was Level III (88304) or Level V (88307) but the claim billed 88305.

The correction is a corrected claim with the right level, not an appeal. Surgical pathology level selection for CPT codes 88302 through 88309 is determined by specimen type and category per the AMA CPT specimen list, not by diagnosis complexity, slide count, or interpretation effort.

CPT 88305 Specimen List: Which Tissues Qualify for Level IV in 2026

The Official AMA Level IV Specimen List (Not an Exhaustive List)

The AMA CPT codebook maintains the Level IV specimen list, and billing cpt code 88305 for a specimen type not on the list is a coding error regardless of how complex the pathologist’s analysis was. The official Level IV specimen list is copyrighted by the AMA.

CPT 88305 Level IV: Confirmed Specimen Categories (per NIH VSAC and MAC educational materials):

[VERIFY the full Level IV specimen list against the current NIH VSAC 88305 entry and AMA CPT codebook before publishing; AMA holds copyright on the specimen list.] CPT 88305 Level IV surgical pathology applies to a defined list of specimen types including colon biopsy, cervix biopsy, endometrium curettings/biopsy, skin (other than cyst/tag/debridement), breast biopsy (not requiring microscopic margin evaluation), prostate needle biopsy, and lymph node biopsy, confirmed by the NIH VSAC code system and MAC educational materials. The level is determined by specimen type, not by the diagnosis discovered during examination.

GI Specimens and Colonoscopy Billing Under CPT 88305

GI biopsy billing is one of the highest-volume 88305 use cases. During a colonoscopy, tissue specimens go to pathology for histologic evaluation. Each separately accessioned specimen from a distinct anatomical site qualifies as a separate billable unit. A colon polyp submitted for pathology is reported with 88305, which is the 88305 cpt code colonoscopy scenario billing teams see most.

The unit rule for GI specimens turns on the jar. A colonoscopy that yields specimens from the transverse colon and the sigmoid colon, submitted in separate jars, generates two units of 88305. Specimens from the same jar, regardless of how many tissue fragments sit inside, generate one unit. The jar determines the unit, not the fragment count.

Common GI specimen types qualify for Level IV: colon biopsy, duodenum biopsy, esophagus biopsy, rectum biopsy, small intestine biopsy, and stomach biopsy. These are all confirmed Level IV categories per the AMA CPT codebook, and each reports under the 88305 cpt code when submitted as a distinct specimen.

ICD-10 context supports these GI claims: K63.5 (colon polyp), K57 (diverticular disease), and K63.3 (ulcer of intestine) are common diagnoses behind GI pathology specimens billed under 88305. [VERIFY K57 and K63.3 subcategory specificity against FY2026 ICD-10-CM before publishing.]

Skin, Breast, Prostate, and Gynecologic Specimens

Skin specimen billing for 88305: skin lesions other than cysts, tags, debridements, and plastic repairs are Level IV per the AMA codebook, confirmed by CAP Today (“All skin specimens other than cysts, tags, debridements, and plastic repairs are coded as 88305”). A basal cell carcinoma excision is 88305 regardless of malignancy. [VERIFY the CAP Today quotation before publishing.]

Breast specimen context: a breast biopsy not requiring microscopic evaluation of surgical margins is 88305. A breast biopsy that does require microscopic margin evaluation is 88307. The distinction comes from the pathology report documentation, per APS Medical Billing’s whitepaper on breast margin coding.

Prostate specimen context carries the article’s most critical transition. Prostate needle biopsy is a confirmed Level IV specimen. For Medicare beneficiaries, the billing code is HCPCS G0416, not the 88305 cpt code. Section 5 below covers this rule in full detail.

Gynecologic specimens round out the high-volume categories: cervix biopsy, endocervix curettings/biopsy, endometrium curettings/biopsy, vagina biopsy, and vulva/labia biopsy are all confirmed Level IV categories. That coverage serves the gynecology lab billing audience, and each maps to the 88305 cpt description for a distinct gyn specimen.

The Per-Specimen Billing Rule: How to Count Billable Units for CPT 88305

What Counts as One Billable Unit Under CPT 88305

Can CPT code 88305 be billed twice? Yes, CPT 88305 can be billed more than once on the same date of service, but only when multiple separately accessioned specimens are submitted. The billing unit is per separately accessioned specimen, not per slide, per tissue block, or per tissue fragment in a jar.

A specimen, for billing purposes, is one distinct tissue sample from a specific anatomical site, separately accessioned in the laboratory. Accession means labeled, logged, and processed as a distinct item. A single accession number corresponds to one billable unit of 88305 regardless of how many tissue fragments sit inside.

The CMS NCCI approach to per-specimen billing ties units of service (UOS) to separately accessioned specimens. Providers billing multiple units of 88305 for a single accession, because multiple slides were prepared, are reporting UOS wrong per CMS NCCI guidance.

Under-separation costs revenue. Three skin lesions submitted in a single jar generate one unit (one accession). Three skin lesions in three separate jars generate three units. A failure to separate specimens at the point of collection is a revenue loss that billing correction can’t fix after the fact.

The Jar Rule: Three Scenarios That Determine Your Units

CPT 88305 Unit Count: Three Billing Scenarios

Clinical staff training determines whether a practice bills the right unit count. When a gastroenterologist submits three polyps from three sites in one jar, the pathology lab has no mechanism to create three accessions from one container.

Billing correction starts with the collection protocol, not with coding. The 88305 cpt code unit count is locked at the moment the surgeon fills the jar.

Specimens placed in separate containers can be billed separately with documentation that each container corresponds to a distinct anatomical site, per a2zbillings’ operational framework cited in the 2026 research. Each container needs its own labeled source site to justify a separate accession, which is the cpt 88305 separation standard payers expect.

Each separately accessioned specimen is billable, but payers impose maximum unit caps per day. Prostate biopsies cap at 16 units per patient per day. GI biopsies cap at 8 units per patient per day per Horizon NJ Health reimbursement policy. Section 8 below covers these MUE limits in full. [VERIFY the 16-unit and 8-unit caps against current Horizon NJ Health reimbursement policy before publishing.]

One O Seven RCM reviews per-specimen unit documentation for pathology claims as part of the pre-submission process, through our revenue cycle management services. Per CMS NCCI billing guidance, CPT 88305 is billed per separately accessioned specimen: one accession equals one billable unit. The number of slides, tissue blocks, or tissue fragments doesn’t increase the unit count.

The 2026 Medicare Alert: G0416 Replaces 88305 for Prostate Needle Biopsies

The CMS NCCI Chapter 10 Rule for Prostate Needle Biopsies

Per CMS NCCI Policy Manual Chapter 10 (effective January 1, 2026), surgical pathology for any and all prostate needle biopsy specimens from a single Medicare patient on a single date of service has to be reported with one unit of HCPCS G0416, not the 88305 cpt code. The CMS NCCI Policy Manual Chapter 10 is the governing authority. [VERIFY the NCCI Chapter 10 G0416 prostate provision and effective date before publishing.]

HCPCS G0416 describes “surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, any number of specimens.” The “any number of specimens” language means that regardless of how many needle biopsy cores are submitted, the billing is one unit of G0416. Not 16 units of 88305. One unit total.

Claims submitted with 88305 for Medicare prostate needle biopsies get denied. This holds regardless of the number of cores, the diagnosis, or the clinical necessity. The payer’s claim processing system applies the rule based on the code submitted and the patient’s Medicare status.

One exception: non-needle prostate specimens, transurethral resection of the prostate (TUR), aren’t subject to the G0416 rule. A prostate TUR specimen reports with 88307, not G0416 and not 88305. The rule applies to needle biopsies.

Which Commercial Payers Have Adopted the G0416 Requirement

Aetna requires G0416 for all prostate needle biopsies effective August 1, 2025, aligning with Medicare rules. Per Aetna’s policy language cited in the 2026 data: claims for surgical pathology for prostate needle biopsy reported with the 88305 cpt code will be denied. [VERIFY Aetna’s G0416 policy and August 1, 2025 effective date before publishing.]

UnitedHealthcare has required G0416 for Medicare beneficiaries’ prostate needle biopsies since January 1, 2021. The 2026 UHC policy states that CPT 88305 won’t be reimbursed for prostate needle biopsy for Medicare beneficiaries. UHC’s commercial (non-Medicare) policy may still accept 88305. [VERIFY UHC’s G0416 policy and January 1, 2021 effective date before publishing.]

For payers not named above and for commercial plan members (non-Medicare), verify payer-specific policy before using G0416. Many commercial plans still accept 88305 per specimen for prostate needle biopsies. Assume G0416 for Medicare, verify for commercial: that’s the operational rule.

For One O Seven RCM’s Texas-based pathology clients, Novitas Solutions (Jurisdiction H, covering Texas) is the Medicare Administrative Contractor; confirm G0416 requirements through Novitas JH’s LCD and billing guidance.

The G0416 vs 88305 Decision Table by Payer and Specimen Type

G0416 vs 88305: Complete Payer and Specimen Decision Table

The G0416 rule is the most denial-prone issue in GI and urology pathology billing workflows, per the 2026 official data sourced from CMS NCCI Chapter 10. The rule has been in effect since G0416’s inception but keeps generating denials because billing teams don’t verify payer status before applying the 88305 cpt code.

Per CMS NCCI Policy Manual Chapter 10, all prostate needle biopsy surgical pathology for Medicare beneficiaries reports with one unit of HCPCS G0416, not CPT 88305. Aetna adopted the same requirement effective August 1, 2025.

Claims using the 88305 cpt code for Medicare prostate needle biopsies get denied.

Modifier Rules for CPT 88305: The Complete 2026 Playbook

Modifier 26 (Professional Component): When to Apply and When NOT to Apply

Modifier 26 is the professional component modifier. You append it to the 88305 cpt code when the pathologist bills only for the interpretation and final report, the professional work of examining slides and rendering a diagnosis. The cpt code 88305 modifier 26 claim line reads 88305-26.

Don’t apply modifier 26 when the same pathologist or pathology group also owns or operates the laboratory and performs the technical work (slide preparation, staining).

Billing 88305-26 when the global service was performed is underbilling, and it can create duplicate payment issues if the TC is also billed by the same entity. A claim missing a required modifier draws a CO-16 missing information denial.

Modifier 26 is most often correct in hospital-based pathology, where the hospital’s lab performs the technical work and the pathologist’s professional group bills separately for interpretation. The hospital or health system bills 88305-TC while the pathology group bills 88305-26.

CGS provides a specific worked example using 88305-26 and 88305-TC for this hospital-inpatient pathology split. [VERIFY the CGS MAC worked example before publishing.]

Modifier TC (Technical Component): The Other Half of Split Billing

Modifier TC (technical component) attaches to 88305 when the lab entity bills only for the technical work, specimen processing, slide preparation, and staining, without billing for the pathologist’s interpretation. The claim line reads 88305-TC.

Modifier TC is most common at independent reference laboratories that process specimens from external ordering providers, where a pathologist at a different entity performs the interpretation. The reference lab bills 88305-TC. The interpreting pathologist bills 88305-26. Neither bills the global code.

Never bill modifier 26 and TC on the same claim line. Use the global code (no modifier) when applicable, per the 2026 official data. Billing both modifiers on one line is a duplicate billing error.

Modifier 90 (reference laboratory) is a separate consideration for reference lab workflows. CPT 88305 includes a professional component (modifier 26: the pathologist’s gross examination, microscopic analysis, and final report) and a technical component (modifier TC: specimen processing, slide preparation, and staining).

When the same entity performs both, bill the global code with no modifier. Per CGS MAC worked examples, hospital-based pathology splits the components between the hospital lab (TC) and the pathologist’s professional group (26).

Global Billing (No Modifier): When One Entity Provides Both Components

When the same entity, a physician office lab, a group practice-owned pathology lab, or a free-standing independent pathology practice, performs both the technical work (slide preparation) and the professional work (interpretation), bill cpt code 88305 with no modifier. The global code covers both components in one payment. This is the standard billing structure for independent pathology practices.

Before selecting a modifier for any 88305 claim, confirm three things: who prepared the slides and processed the specimen; who examined the slides and signed the final report; and whether these are the same entity or different entities. Those three answers decide whether to bill the global code, 26, TC, or both as a split.

Modifier 59, XU, and 91: When Additional Modifiers Apply

Modifier 59 (distinct procedural service) attaches to the 88305 cpt code when multiple specimens from distinct anatomical sites are billed on the same date and the payer’s claim editing system requires distinction between them. The documentation has to support that each specimen is from a separate anatomical site.

Modifier XU (unique service), per providerscarebilling’s research, applies when a service is unique and doesn’t overlap with other services performed the same day. For 88305, that means a separate tissue specimen from an unrelated site examined alongside the primary specimen. XU distinguishes the service from other bundled services on the claim.

Modifier 91 (repeat clinical diagnostic laboratory test) applies when 88305 is performed again on the same date of service for a medically necessary reason. The repeat needs clinical justification and documentation apart from the initial examination.

2026 Modifier Quick Reference for CPT 88305

2026 Medicare Fee Schedule for CPT 88305: Named Rates from Official Sources

The 2026 Medicare National Rates: Three Numbers Every Billing Team Needs

The 2026 Medicare fee schedule for the 88305 cpt code comes from the College of American Pathologists (CAP) CMS Impact Table (July 2025 update), which tracks changes in the CMS Physician Fee Schedule each year. These are national unadjusted rates before GPCI locality adjustment. [VERIFY all three rates and the wRVU against the CAP CMS Impact Table (July 2025) and CMS RVU26B before publishing.]

CPT 88305: 2026 Medicare National Payment Rates (Unadjusted)

The wRVU for CPT 88305 is 1.90, per the CMS RVU26B release (April 2026, updated 05/01/2026). CMS maintains the Physician Fee Schedule Look-Up Tool for code-by-code verification at the MAC locality level.

The CY 2026 PFS Final Rule (CMS-1832-F) finalized two separate conversion factors for Qualifying APM Participants (QPs) and non-QPs, along with a negative 2.5% efficiency adjustment, and those factors shift what providers receive versus the national unadjusted rate.

CMS also publishes the PFS National Payment Amount File (PFREV26A, effective January 2026) for bulk rate lookups. For pathology labs billing at high volume, that file runs faster than code-by-code lookups. Billing teams should align claim scrubbers to the current quarter’s RVU release.

What Determines Your Actual Reimbursement: GPCI, Setting, and MAC Locality

Three variables determine what a specific provider receives for 88305 beyond the national rate: the Geographic Practice Cost Index (GPCI) adjustment applied by the MAC locality; the place of service (facility vs. non-facility differential); and contractual rates for commercial payers.

Facility vs. non-facility matters for pathology. For Medicare Part B professional claims from pathologists in hospital settings, the physician fee schedule applies. For hospital outpatient department technical claims, OPPS (Outpatient Prospective Payment System) rates apply to the TC component, set apart from the PFS.

Commercial payer reimbursement runs higher. Per Bing AI Overview data citing anrmedicalbilling.com, commercial payers reimburse 88305 in the range of $90 to $120 per unit. That’s a market range, not an official rate, and actual commercial rates depend on contracted fee schedules.

The 88305 cpt code reimbursement a lab collects from a commercial plan tracks its contract, not the Medicare baseline. [VERIFY the commercial range against current source data before publishing.]

Patient cost for CPT 88305 depends on the payer’s cost-sharing rules (deductible, coinsurance), plan type, and whether the lab is in-network. The billing team can’t determine patient cost from the CPT code alone.

MUE Limits and Maximum Units for CPT 88305 by Diagnosis Category

Daily Maximum Units by Diagnosis: The 2026 Payer Limits Table

Payers cap the maximum units of the 88305 cpt code billable per patient per date of service. These caps prevent overbilling on high-volume specimen days, colonoscopies with multiple polyps, prostate needle biopsies with multiple cores. The caps vary by diagnosis category and payer. Overriding them without documentation support draws an automatic claim denial.

CPT 88305: Daily Maximum Units by Diagnosis Category (2026)

The Horizon NJ Health caps for rows 1 and 2 come from the Horizon NJ Health reimbursement policy. [VERIFY all unit caps against current Horizon NJ Health policy before publishing.] MUE values update quarterly through CMS. Billing teams shouldn’t rely on annual cheat sheets for unit limits.

As of May 28, 2026, CMS posted the latest MUE quarterly update with files effective July 1, 2026. Aligning claim scrubbers to the current quarter’s MUE table heads off denials from outdated unit caps.

The 88305 cpt code unit limit a scrubber enforces has to match the live quarter. [VERIFY the May 28, 2026 MUE posting date and July 1, 2026 effective date before publishing.]

Claims exceeding the MUE can be payable on appeal: per CMS MAC education, MUE Adjudication Indicator (MAI) “3” edits may pay on appeal with adequate documentation. A billing team with documented clinical justification for exceeding the standard unit cap can recover the payment through an appeal with supporting records.

The Sentara Health Plans May 2026 Policy Update: What Changed

Per the Sentara Health Plans Operations Update dated May 14, 2026, CPT 88305 is now subject to Daily Maximum Frequency editing for Sentara Health Plans. Claims exceeding the daily maximum frequency defined in Sentara’s policy get reduced or denied at adjudication. The Sentara Health Plans policy page carries the update. [VERIFY the Sentara May 14, 2026 Operations Update and the Daily Maximum Frequency editing provision for 88305 before publishing.]

Sentara Health Plans is a regional payer covering Virginia, North Carolina, and surrounding markets. Pathology labs billing Sentara for high-volume colonoscopy or dermatology days need to verify the specific maximum frequency threshold Sentara defined for 88305 under this editing policy.

The Sentara update reflects a 2026 trend: commercial payers are tightening daily maximum frequency controls on high-volume pathology codes, following CMS’s MUE precedent. Billing teams should monitor payer-specific policy updates each month, not just annual fee schedule changes, for the codes driving their highest claim volume.

Billing teams handling 88305 claims for Sentara beneficiaries should contact Sentara’s provider relations team to confirm the maximum frequency threshold and the appeal process under the new policy.

Per Horizon NJ Health reimbursement policy and CMS-aligned guidelines, the daily maximum units for CPT 88305 are 16 units for prostate diagnoses (ICD-10 C61, D29.1) and 8 units for gastrointestinal diagnoses (ICD-10 C18).

In May 2026, Sentara Health Plans announced that CPT 88305 is now subject to Daily Maximum Frequency editing.

NCCI Bundling Rules for CPT 88305: What Cannot Be Separately Billed

The 88300 Prohibition: Why Gross-Only Cannot Be Billed Alongside 88305

Per CMS NCCI Policy Manual Chapter 10 (effective January 1, 2026), CPT 88300 (gross examination only, Level I surgical pathology) must not be reported alongside CPT 88302 through 88309 for the same specimen. Gross examination is integral to all surgical pathology gross-plus-microscopic codes. The CMS NCCI Policy Manual Chapter 10 governs the rule.

Because 88305 already includes the gross examination as a mandatory component (confirmed in Section 1’s documentation requirements), billing 88300 in addition to 88305 for the same specimen double-bills a service already included. The payer’s edit system flags the pair and applies a bundling denial, a CO-97 NCCI bundling denial in most cases.

When NCCI Procedure-to-Procedure edits apply to the 88300+88305 pair, the claim draws a CO-236 NCCI PTP edit denial. That’s a different denial code than CO-97, but the root cause matches: the gross examination is included in the higher-level code.

The fix: remove 88300 from the claim. If the gross examination was the only service performed (no microscopic examination), the correct code is 88300 alone, not 88305 and not both codes together. The correction depends on what the pathologist performed.

A bone marrow NCCI exception applies: if only one specimen is submitted for surgical pathology, only one surgical pathology code (88305 or 88307 as appropriate) reports even when the report includes evaluation of both bone structure and bone marrow.

The 88305 cpt code stands alone on that single-specimen claim. Per CMS NCCI Policy Manual Chapter 10, billing 88300 with 88305 for the same specimen constitutes unbundling, and the payer returns a CO-97 or CO-236 denial; the correct action is to remove 88300.

IHC Add-On Codes (88342, 88341): What Is and Is Not Separately Billable

Code 88342 (immunohistochemistry, first antibody) is separately billable alongside the 88305 cpt code when an IHC stain is ordered, performed, and separately interpreted. Per CMS NCCI Chapter 10, the unit of service for IHC is per stain procedure per specimen, not per block, not per slide. That distinction is the most common billing error in add-on IHC coding.

88305 Add-On Code Reference: What’s Separately Billable

When a payer determines that an IHC add-on code isn’t separately payable alongside 88305 (due to payer-specific bundling policy rather than NCCI edits), the denial code is CO-234 not separately payable. This happens when a commercial payer’s reimbursement policy restricts IHC billing beyond CMS NCCI rules. [VERIFY the INT-8 CO-234 URL slug, which reads “o-234-denial-code-description” and may be a typo for “co-234”.]

Performing a stain across multiple slides or blocks from the same specimen doesn’t justify additional units. Per CMS NCCI Chapter 10, controls aren’t separately reportable units for special stains or IHC.

ICD-10 Codes That Support Medical Necessity for CPT 88305

Payers evaluate CPT codes and ICD-10 codes together during automated claim adjudication. An ICD-10 code that doesn’t correspond to the specimen type billed under 88305 draws an automatic CO-11 denial for diagnosis-procedure mismatch.

The correct ICD-10 code documents both the specimen source and the clinical indication for the examination. Pair the 88305 cpt code with a diagnosis that matches the tissue submitted.

CPT 88305: ICD-10 Code Pairing by Specimen Type (2026)

[VERIFY every ICD-10 code and descriptor in this table against the FY2026 ICD-10-CM tabular list before publishing.]

Use the most specific ICD-10 code available. Unspecified codes (those ending in .9 or .0) hold up only when the clinical documentation doesn’t carry enough detail for a more specific code. Payers now deny claims with unspecified codes when a more specific alternative exists for the condition.

For GI specimen ICD-10 context, see the abdominal pain ICD-10 codes reference at One O Seven RCM.

ICD-10 Mismatch Patterns That Trigger Automatic Denial

The first mismatch pattern: billing 88305 for a prostate needle biopsy on a Medicare claim with ICD-10 C61, using 88305 instead of G0416. The payer’s editing system flags the CPT code, and the ICD-10 pairing signals the same mismatch to the audit logic. The correction routes through the CO-11 diagnosis-procedure mismatch workflow.

The second pattern: billing 88305 with a non-specific Z-code (observation or screening) as the primary diagnosis when the clinical record supports a definitive diagnosis. Payers deny on medical necessity grounds when the diagnosis code doesn’t establish the clinical necessity for a tissue examination. That draws CO-50, not CO-11.

The third pattern: using a symptom code (R-category) as the primary diagnosis when a confirmed pathology diagnosis is available from the report. When the pathology report confirms malignancy, the malignancy code (C-category) becomes the primary diagnosis on the claim, replacing the original symptom code.

The ICD-10 update cycle is the fourth exposure. CMS updates ICD-10-CM each year, with the FY2026 update effective October 1, 2025. Pathology billing teams running outdated diagnosis codes risk denials from invalid code submissions. Confirm that your EHR’s ICD-10-CM code set runs the FY2026 version for all claims with dates of service on or after October 1, 2025.

Documentation Requirements: What MAC Reviewers Actually Look For

MAC documentation requirements for 88305 reach past what the AMA descriptor requires. The Palmetto GBA surgical pathology review checklist, covering 88305 through 88309, defines four documentation elements that have to be present for a claim to pass post-payment review.

A claim missing any one of them draws a denial, even when every other coding element is correct. The 88305 cpt code documentation standard sits at the MAC level, not the codebook level.

Palmetto GBA Surgical Pathology Documentation Requirements (CPT 88305-88309)

Palmetto GBA lists 88305 among laboratory codes subject to post-payment medical review (Palmetto GBA surgical pathology review checklist). [VERIFY the four Palmetto GBA documentation elements and the post-payment review listing against current Palmetto GBA guidance before publishing; the blueprint supplied no live Palmetto URL.] A claim that passes initial adjudication can still face retroactive review and denial when documentation falls short of these four requirements. Post-payment denial draws a CO-252 missing documentation demand.

CGS MAC Probe Review Findings: The Missing Documentation Most Billing Teams Ignore

CGS Administrators, the J15 MAC covering Kentucky, Ohio, and Indiana among other areas, published results of a probe review for CPT 88305. The two primary failure patterns: documentation didn’t support the 88305 level billed (wrong level), and no documentation of the treating clinician’s order or intent to order was present, even when a complete, signed pathology report existed. [VERIFY the CGS J15 probe review findings and jurisdiction details against current CGS guidance before publishing.]

A signed pathology report doesn’t stand on its own. The treating clinician’s order or intent to order has to exist in the record independent of the pathology report. This is the most common documentation failure for 88305 claims on MAC review, and it can’t be corrected once the specimen has been processed.

Before submitting 88305 claims, confirm that a signed physician order sits on file alongside the pathology report. When the ordering provider used a verbal or electronic order system, the documentation of that order has to be retrievable. Missing order documentation draws CO-50 medical necessity or CO-252.

CGS provides a worked billing example using 88305-26 (professional component, pathologist’s group) and 88305-TC (technical component, hospital lab) for hospital inpatient pathology services. That example shows the PC/TC split billing structure in a real MAC-documented scenario, covered in full in the place-of-service section below.

Top 2026 Denial Triggers for CPT 88305: CARC Denial Matrix

88305 denials follow eight predictable patterns in 2026. Each one maps to a specific CARC code, a specific root cause, and a specific resolution path. Billing teams that misread the root cause burn time on the wrong workflow.

The matrix below names each pattern and the correct route. Work the 88305 cpt code denials by category, not one claim at a time.

CPT 88305: 2026 CARC Denial Matrix

The resolution hierarchy sorts these into two buckets. CO-50 and CO-197 denials need clinical documentation and formal appeals. CO-97, CO-236, CO-16, and CO-11 denials are correctable claims, fixable and resubmitted without a formal appeal in most cases. CO-252 denials need document submission to the payer’s portal or fax line inside the resubmission window. Don’t mix the workflows between buckets.

CO-252 and CO-50 denials on 88305 claims are the slowest to clear because they pull documentation from clinical staff, route through the payer portal, and wait on re-adjudication. These age into the 60-90 day AR bucket fast. Practices with high 88305 volume should flag both codes for priority resolution inside the first 14 days of receipt.

Hand Pathology Denials to a Team That Works the Root Cause

One O Seven RCM’s denial management team handles CPT 88305 denial resolution across all eight CARC categories, from NCCI bundling corrections through MAC documentation appeals. Our pathology billing team reads the root cause of each denial before routing it to the right workflow. Start with denial management services.

For 88305 claims already in the 60-90 day AR bucket with CO-252 or CO-50 denials, our AR follow-up services team prioritizes documentation retrieval and resubmission before timely filing deadlines close the recovery window.

The 88305 denial patterns above haven’t changed in 2026, but the Sentara Health Plans frequency editing update and the July 1, 2026 NCCI MUE changes mean the volume of preventable denials is climbing, not falling.

Place of Service and PC/TC Split Billing by Setting

The place of service code on a 88305 cpt code claim sets two things: which reimbursement rate applies (facility vs. non-facility) and which entity bills which component. A wrong place of service draws CO-16 for incorrect claim data and can trigger a facility-versus-professional conflict when two entities submit claims for the same service in incompatible settings.

CPT 88305: Place of Service and PC/TC Billing Rules by Setting

The most common billing conflict: billing 88305 as the global code from a hospital outpatient setting where the hospital’s lab processes the slides. The hospital has to bill 88305-TC on the facility claim (UB-04).

When the pathologist’s group also bills 88305 as the global code on a CMS-1500, the payer sees duplicate billing and denies one claim. The correct split is 88305-26 from the pathologist and 88305-TC from the facility.

The reference lab modifier 90 rule for the 88305 cpt code applies when an independent laboratory processes the specimen but sends it to an outside reference lab for technical processing. The billing lab (the referring lab) reports the code with modifier 90. The reference lab doesn’t bill the patient, it invoices the referring lab.

For hospital-based pathology claims in Texas, Novitas Solutions (Jurisdiction H, JH) is the Part B MAC. Pathology groups billing 88305-26 for Texas hospital inpatient cases should confirm billing instructions with Novitas JH. [VERIFY: the blueprint labeled the Texas MAC “J15,” which is CGS Administrators (KY, OH, IN); the correct Texas Part B MAC is Novitas Solutions, Jurisdiction H. Corrected here.]

Frequently Asked Questions About CPT Code 88305 Billing in 2026

Can CPT code 88305 be billed more than once on the same claim?

Yes. CPT 88305 can be billed multiple times on a single claim when multiple separately accessioned specimens are submitted from distinct anatomical sites. Each accession number corresponds to one billable unit. Three polyps from three separately labeled containers generate three units (88305 x3). Three polyps in one container generate one unit. The jar, not the fragment count or the slide count, sets the unit.

What is the maximum number of units allowed for CPT 88305?

The maximum daily units for CPT 88305 depend on the diagnosis category. Per Horizon NJ Health reimbursement policy and commercial payer alignment, the standard limits run 16 units per patient per day for prostate diagnoses (ICD-10 C61, D29.1) and 8 units for gastrointestinal diagnoses (ICD-10 C18). CMS updates MUE values quarterly. Billing teams should align claim scrubbers to the current quarter’s MUE table, not an annual cheat sheet.

What is the difference between CPT 88305 and CPT 88307?

CPT 88305 is Level IV surgical pathology for moderate-complexity specimens: skin biopsies, GI biopsies, cervical biopsies, breast core biopsies that don’t require surgical margin evaluation, and single lymph nodes. CPT 88307 is Level V for complex specimens requiring detailed surgical margin documentation or organ resection analysis. The cpt code 88305 level turns on specimen type and required work per the AMA CPT specimen list, not on diagnosis complexity.

Is CPT 88305 a lab code?

CPT 88305 is a procedural billing code, not a CLIA laboratory test code. It belongs to the Pathology and Laboratory Procedures section of the AMA CPT codebook (codes 80047-89398) and serves billing and reimbursement. The laboratory performing the test has to hold CLIA certification, but 88305 itself is a CPT code describing a surgical pathology service. CLIA codes and CPT codes are different systems built for different purposes.

Can CPT codes 88305 and 88342 be billed on the same claim?

Yes. CPT 88342 (immunohistochemistry, first antibody) is separately billable alongside 88305 when an IHC stain is ordered, performed, and separately interpreted by the pathologist. Per CMS NCCI Chapter 10, the unit of service is per stain procedure per specimen, not per slide or block. CPT 88341 (each additional antibody) is also separately billable as an add-on to 88342. Some commercial payers restrict IHC billing under their own policy, so verify payer rules before submitting add-on codes.

What place of service code applies to CPT 88305?

The place of service for 88305 depends on where the service is performed. Hospital on-campus outpatient labs use POS 22. Physician office labs use POS 11. Free-standing independent laboratories use POS 81. Ambulatory surgical center labs use POS 24. The place of service sets which reimbursement rate applies and which entity bills which component. In hospital settings, the facility bills 88305-TC and the pathologist’s group bills 88305-26.

What is CLIA code 88305?

There’s no CLIA code 88305. This is a common search confusion between two coding systems. 88305 is a CPT code (Current Procedural Terminology) maintained by the American Medical Association for billing surgical pathology services. CLIA (Clinical Laboratory Improvement Amendments) codes govern laboratory certification categories and don’t use CPT code numbers. The laboratory performing the 88305 service has to hold CLIA certification, but 88305 is the billing code, not a CLIA test code.

The Bottom Line for Pathology Billing Teams: What to Do Before the Next 88305 Claim Goes Out

Run four compliance checks before any 88305 cpt code claim goes out in 2026: verify payer status (Medicare means G0416 for prostate needle biopsies, not 88305); confirm per-specimen jar separation at the point of collection; confirm the signed treating clinician order is on file; and verify the modifier selection matches the billing entity’s role. Those four checks stop most preventable denials before they post.

Two 2026 watch items sit on top of the standing rules. The July 1, 2026 NCCI MUE update changes how some 88305 claim pairs process. The Sentara Health Plans frequency editing policy (effective May 2026) adds a new commercial payer control layer. Billing teams that treat 88305 as a routine code and skip quarterly policy review build a denial backlog. Review payer-specific policies every quarter.

One O Seven RCM manages 88305 billing compliance for pathology labs and multi-specialty practices across all payer types. From specimen classification through denial recovery, our team keeps pathology claims moving with revenue cycle management services built for the volume these claims run.

This guide reflects CMS NCCI Policy Manual Chapter 10 (effective January 1, 2026), the College of American Pathologists CMS Impact Table (July 2025 update), the CMS Physician Fee Schedule and CY2026 PFS Final Rule (CMS-1832-F), Palmetto GBA and CGS MAC surgical pathology documentation guidance, and the CMS MUE quarterly posting effective July 1, 2026, current as of the publish date. CPT codes and descriptors are copyrighted by the American Medical Association. The AMA Level IV specimen list is maintained by the AMA; specimen categories here are confirmed through the NIH VSAC code system and MAC educational materials. Verify all codes, rates, MUE limits, LCD coverage, and payer policies against current CMS, MAC, and payer sources before claim submission. Authored by Carter Hensley, CPC (AAPC), One O Seven RCM.